COMPASS (rivaroxaban alone), 2017 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of rivaroxaban versus aspirin in Patients With Coronary or Peripheral Artery Disease

        Z

NCT01776424    



Studied treatment Rivaroxaban 2.5 mg twice daily alone
Control treatment aspirin 100 mg once daily

3 arms rivaroxaban and aspirin, rivaroxaban alone, aspirin alone



Patients Patients With Coronary or Peripheral Artery Disease
Size27400
smokers (%)
familly history of CHD
Systolic blood pressure (mmhg)
Cholesterol total (mmol/L)



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI CV events - 27400 - 0 no data fatal stroke - 27400 - 0 no data CV death (IHD+stroke) - 27400 - 0 no data non fatal IHD - 27400 - 0 no data Haemorrhagic stroke - 27400 - 0 no data all causes deaths - 27400 - 0 no data ischemic heart disease - 27400 - 0 no data all stroke - 27400 - 0 no data ischemic stroke - 27400 - 0 no data IHD death - 27400 - 0 no data major bleeding - 27400 - 0 no data0,22,01,0

Links

NEJM

ClinicalTrial.gov record NCT01776424



Registering number NCT01776424 (see trial on clinicaltrials.gov)
Code Name